Improving medication adherence for cardiovascular patients through community pharmacists
Community Pharmacist Intervention to Enhance Adherence in Cardiovascular Drug Initiators
This study tests whether working with community pharmacists can help people who are starting new heart medications take them as prescribed and feel supported during the process.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Ghent Academic / other |
| Locations | 1 site (Ghent) |
| Trial ID | NCT06142838 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates a community pharmacist intervention designed to enhance medication adherence among patients who are newly prescribed medications for cardiovascular disease prevention. The study aims to determine the effectiveness of this intervention, identify which patients benefit the most, and explore patients' experiences with starting new medications, including any questions or side effects they may encounter. Additionally, it seeks to understand the experiences of both patients and pharmacists during the intervention process.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are starting their first prescription for specific cardiovascular medications.
Not a fit: Patients prescribed cardiovascular medications for non-cardiovascular indications or those unable to communicate effectively due to cognitive impairment or language barriers may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve medication adherence among patients at risk for cardiovascular diseases, leading to better health outcomes.
How similar studies have performed: Other studies have shown that pharmacist interventions can improve medication adherence, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients presenting with a first prescription for one of the following drug classes: antihypertensive drugs (= low-ceiling diuretics, beta blocking agents (excl. non-selective beta-blocking agents), ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers), lipid-lowering drugs (= statins), antidiabetic drugs (= metformin, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose co-transporter 2 (SGLT2) inhibitors), or any combination thereof. * Age 18 years or older * Community-dwelling Exclusion Criteria: * The drug is prescribed for a non-cardiovascular indication (e.g. beta-blocking agent for migraine prophylaxis) * Communication with the patient is not possible (e.g. due to cognitive impairment, insufficient knowledge of Dutch or French language)
Where this trial is running
Ghent
- Pharmaceutical Care Unit (Ghent University) — Ghent, Belgium (Recruiting)
Study contacts
- Study coordinator: Els Mehuys
- Email: els.mehuys@ugent.be
- Phone: +32478509830
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.